about
Advances and hurdles on the way toward a leprosy vaccine.Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosyImmunologically reactive M. leprae antigens with relevance to diagnosis and vaccine developmentAnalysis of antigens of Mycobacterium leprae by interaction to sera IgG, IgM, and IgA response to improve diagnosis of leprosy.Evaluation of novel tools to facilitate the detection and characterization of leprosy patients in ChinaInsight toward early diagnosis of leprosy through analysis of the developing antibody responses of Mycobacterium leprae-infected armadillos.From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.Advances in Proteomics of Mycobacterium leprae.Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil.Synergistic antigen combinations for the development of interferon gamma release assays for paucibacillary leprosy.Evaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosy.Challenges in the post genomic era for the development of tests for leprosy diagnosis.Enhancing sensitivity of detection of immune responses to Mycobacterium leprae peptides in whole-blood assays.The potential for vaccination in leprosy elimination: new tools for targeted interventions.A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.Mycobacterial r32-kDa antigen-specific T-cell responses correlate with successful treatment and a heightened anti-microbial response in human leprosy patients.LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection.Mycobacterium leprae-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT.Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect AgainstEvaluation of antigen-specific immune responses for leprosy diagnosis in a hyperendemic area in China
P2860
Q22305432-457DCCBF-36D6-4C7C-8273-9CEF01100C8DQ26749927-D9493F2E-E64B-4B29-8DEA-58D5848CBBBEQ33804328-657CB740-3210-4BDE-96D2-F9055265D669Q33914906-81F52903-73C1-4FB7-BE86-66C2D60B4C5BQ34092922-D2B2C551-84F7-4468-BDCD-A0507B1F9CFEQ34738846-6AB766A5-8A3B-4965-A20B-2C7D1EE46E9FQ35809113-ED8AAB87-2800-42EB-835F-7CE560D8428EQ37451046-C44CEEC0-DBA9-4FD0-988B-DE4C9065D449Q37974318-F821331F-9AB7-4681-B982-D563B79AC630Q39088060-7488DD51-91FC-44DB-BCED-4B8F5045C0A5Q39322347-B9699143-106A-462B-AFE3-CE52DBC59010Q39426951-7010F0CF-3A0A-417E-8AA1-87C1DC614809Q39488291-9DD88F79-1713-47B7-8DE1-50945A578851Q41013632-6B464FCF-3A85-465E-86CC-76833E4F5DF7Q42279572-D3A462E8-7281-43EC-8787-A775837D1AF3Q47136266-730C566E-2EFA-4DF7-B8B8-901F3F48AEB4Q50204183-90A75AB1-B76D-4033-9593-3D9926AABFE8Q52605965-FD6BC48A-8B8F-41C1-9A12-6792BE6BD43AQ55287217-3CBE7856-EC79-4527-A0E6-158E8A949873Q58606318-CD08428B-9666-4C4C-9560-8A0929B37254Q58701503-0F655305-C936-4E69-B021-C69702CE0DDA
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Antigen-specific T-cell responses of leprosy patients
@en
type
label
Antigen-specific T-cell responses of leprosy patients
@en
prefLabel
Antigen-specific T-cell responses of leprosy patients
@en
P2093
P2860
P356
P1476
Antigen-specific T-cell responses of leprosy patients
@en
P2093
A B Grassi
Ana Lucia M Sousa
Celina M T Martelli
Greg C Ireton
Lucas H Sampaio
Mariane M A Stefani
Stephen T Reece
Wakako Goto
P2860
P304
P356
10.1128/CVI.00234-08
P577
2008-09-10T00:00:00Z